Podcast

August 11, 2019

Podcast: This Week in Managed Care—Pancreatic Cancer Screening and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Care^® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care news included HHS laying out a plan for importing certain prescription drugs from other countries; a potential new standard of care for chronic lymphocytic leukemia; 3 insulin makers get subpoenaed over their pricing practices.

Listen above or through one of these podcast services:

CMS Gives CAR T Payments Short-term Boost, Adjusts Hospital Wage Index

Still No Call for Widespread Screening for Pancreatic Cancer, but USPSTF Says Yes for Those With Known Risk

What We're Reading: FDA Says Novartis Hid Data; Judge Halts Ark. Abortion Rules; New Phase in Opioid Suits

One Dose of HPV Vaccine Effective in Preventing Cervical Cancer Compared With Multiple Doses, Researchers Say

"Not So Different": The Biosimilars Council Says Patent Abuses Are Costing Biosimilar Savings

Read more about the stories in this podcast:

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos

CK Wang, MD, COTA

Eric Lander, MD

Eric Lander, MD

David Awad, PharmD, BCOP

Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center

Coral Omene, MD, PhD, sitting for a vieo interview

David Awad, PharmD, BCOP

Coral Omene, MD, PhD, sitting for a vieo interview

Related Content

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

June 27th 2025

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

Kimberly Rath, PharmD

Elevated NLR may no longer predict poor survival outcomes in patients with small cell lung cancer (SCLC) receiving immunotherapy, according to new research.

Managed Care Cast

June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com

June 22nd 2025

Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

Laura Joszt, MA Coral Omene, MD, PhD

Delivering value-based cancer care requires overcoming hurdles to access care and tailoring care that prioritizes the quality-of-life metrics the patient values, explained Coral Omene, MD, PhD.

June 19th 2025

Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays

Maggie L. Shaw Colin Banas, MD, MHA

Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com

June 18th 2025

Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

Jared Kaltwasser

A teledermatology program in Georgia helped identify patients with skin lesions that warranted in-person follow-up with a physician.

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

June 13th 2025

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

Jared Kaltwasser

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

Related Content

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

June 27th 2025

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

Kimberly Rath, PharmD

Elevated NLR may no longer predict poor survival outcomes in patients with small cell lung cancer (SCLC) receiving immunotherapy, according to new research.

Managed Care Cast

June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com

June 22nd 2025

Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

Laura Joszt, MA Coral Omene, MD, PhD

Delivering value-based cancer care requires overcoming hurdles to access care and tailoring care that prioritizes the quality-of-life metrics the patient values, explained Coral Omene, MD, PhD.

June 19th 2025

Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays

Maggie L. Shaw Colin Banas, MD, MHA

Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com

June 18th 2025

Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

Jared Kaltwasser

A teledermatology program in Georgia helped identify patients with skin lesions that warranted in-person follow-up with a physician.

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

June 13th 2025

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

Jared Kaltwasser

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions